EAST WINDSOR, N.J.--()--NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT® drug delivery technology, today announced that Vivian Liu, Chief Executive Officer, will present an overview of the company at the BIO CEO & Investor Conference on Tuesday, February 10, 2009 at 11 am (ET) at the Waldorf Astoria Hotel in New York City.
BIO CEO is the largest independent investor conference focused on leading publicly traded biotech companies, and is designed to appeal to public market investors as well as the sell-side investment community, in addition to business development executives from global pharmaceutical and biotechnology companies.
Interested parties may access the live webcast of NexMed’s presentation on the Company’s website (Investors: News & Events) at http://www.nexmed.com.
About NexMed
NexMed, Inc. leverages its proprietary NexACT drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. NexMed’s novel onychomycosis treatment is licensed to Novartis for global development. NexMed’s pipeline also includes its late stage alprostadil treatment for erectile dysfunction, a Phase 2 treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
Email 
